McElhinney R S, McCormick J E, Bibby M C, Double J A, Atassi G, Dumont P, Pratesi G, Radacic M
Laboratory of the Medical Research Council of Ireland, Trinity College, Dublin.
Anticancer Drug Des. 1989 Oct;4(3):191-207.
The synthesis of representative seco-nucleoside analogues of 5-fluorouracil (5-FU)/nitrosourea molecular combinations having uracil (U) as base instead of 5-FU is described. The anti-tumour activity of corresponding pairs of drugs is compared in experimental tumours of the mouse colon, lung and breast. These studies have demonstrated that the presence of a hydrogen or fluorine atom at pyrimidine C-5 is unimportant for the activity shown against most of the experimental tumours employed, rather that the pyrimidine cyclic urea and/or alkylthio functionalities may constitute the critical factors. One exception is the prototypical compound B.3839 and its U analogue B.3912. B.3839 is highly active against colon 38 adenocarcinoma, a tumour which is highly responsive to 5-FU, whereas most of the activity is lost in B.3912. The 5-FU release profile of some of these molecular combinations could be adequate or effective in treatment of slow-growing clinical tumours.
本文描述了以尿嘧啶(U)为碱基而非5-氟尿嘧啶(5-FU)的5-氟尿嘧啶/亚硝基脲分子组合的代表性开环核苷类似物的合成。在小鼠结肠、肺和乳腺的实验肿瘤中比较了相应药物对的抗肿瘤活性。这些研究表明,嘧啶C-5位上氢原子或氟原子的存在对所采用的大多数实验肿瘤的活性并不重要,相反,嘧啶环脲和/或烷硫基官能团可能是关键因素。一个例外是原型化合物B.3839及其U类似物B.3912。B.3839对结肠38腺癌具有高活性,该肿瘤对5-FU高度敏感,而B.3912的大部分活性丧失。其中一些分子组合的5-FU释放曲线在治疗生长缓慢的临床肿瘤中可能是足够的或有效的。